GB Sciences, Inc. reported its financial results for the three and nine months ended December 31, 2024, revealing a revenue of $97,235, a significant increase from zero revenue in the same period last year. The company attributed this revenue to a new licensing agreement with EndoPure Life Sciences, LLC, which allows EndoPure to develop and market pharmaceutical products based on GB Sciences' intellectual property. Despite this revenue, the company recorded a net loss of $100,355 for the quarter, an improvement from a loss of $187,276 in the prior year, and a net loss of $575,899 for the nine months, down from $894,630 in the same period last year.
General and administrative expenses decreased to $163,826 for the three months ended December 31, 2024, compared to $234,007 in the same quarter of 2023. This reduction of $70,181 reflects the company's ongoing efforts to minimize administrative costs while advancing its research and development initiatives. Interest expenses also saw a decline, totaling $33,764 for the quarter, down from $38,269 a year earlier, primarily due to the amortization of debt discounts.
Operationally, GB Sciences has made strides in its research and development efforts, focusing on plant-inspired medicines. The company has a portfolio of intellectual property that includes eight U.S. and twelve foreign patents, with ongoing preclinical studies for various therapeutic programs, including treatments for Parkinson's disease and chronic pain. The company is also exploring partnerships to advance its drug development programs, particularly for its Parkinson's disease therapy, which is expected to enter clinical trials soon.
As of December 31, 2024, GB Sciences reported total current assets of $94,467, a decrease from $103,442 at the end of the previous fiscal period. Current liabilities increased to $5,417,481 from $5,095,557, leading to a working capital deficit of $5,323,014. The company’s cash position has also declined, with cash and cash equivalents at $3,016 compared to $11,991 at the end of March 2024. The company continues to seek additional financing to support its operations and growth plans, as it faces substantial doubt about its ability to continue as a going concern without securing further capital.
Looking ahead, GB Sciences aims to leverage its licensing agreement and ongoing research to enhance its market position in the biopharmaceutical sector. The company is actively pursuing additional funding sources to ensure it can meet its operational needs and continue its development efforts. However, the ability to achieve profitable operations remains uncertain, contingent on successful financing and the outcomes of its clinical trials.
About GB SCIENCES INC
GB Sciences, Inc. is a biopharmaceutical company developing plant-inspired medicines, primarily from cannabis and traditional herbs. Through its Canadian subsidiary, it creates patented formulations targeting diseases like Parkinson’s, pain, inflammation, and mental health conditions. Utilizing AI-driven drug discovery and strategic partnerships, it focuses on patent-protected, minimally complex mixtures for prescription therapies, aiming to address unmet medical needs in global markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.